



Contraceptive eligibility for women at high risk of HIV

Guidance statement

Recommendations on contraceptive methods used by women at high risk of HIV

Contraceptive eligibility for women at high risk of HIV

Guidance statement

Recommendations on contraceptive methods used by
women at high risk of HIV



**World Health
Organization**

Contraceptive eligibility for women at high risk of HIV. Guidance statement: recommendations on contraceptive methods used by women at high risk of HIV

ISBN 978-92-4-155057-4

© World Health Organization 2019

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Contraceptive eligibility for women at high risk of HIV. Guidance statement: recommendations on contraceptive methods used by women at high risk of HIV. Geneva: World Health Organization; 2019. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The views expressed in this publication are those alone of the named authors and of the collective views of an international group of experts and do not necessarily represent the decisions or the policies of WHO.

Printed in Switzerland

CONTENTS

	ACKNOWLEDGEMENTS	V
	ABBREVIATIONS	VI
	EXECUTIVE SUMMARY	VII
1	BACKGROUND	1
2	METHODS OF GUIDELINE REVIEW AND DEVELOPMENT	2
	2.1 Guideline Development Group	2
	2.2 Guideline development process	2
	2.3 Evidence Retrieval	3
	2.4 Evidence Synthesis	4
	2.5 Formulation of recommendations	4
3	SUMMARY OF THE EVIDENCE	4
	3.1 Progestogen-only injectables	5
	3.2 Progestogen-only implants	5
	3.3 Progestogen-only pills	5
	3.4 Intrauterine devices	5
	3.5 Combined hormonal contraceptives	5
	3.6 Additional evidence considered by the GDG	5
	3.6.1 Biological data	5
	3.6.2 Values and preferences of contraceptive users	6
4	RECOMMENDATIONS	6
	4.1 Recommendations for contraceptive use among women at high risk of HIV infection	6
	4.2 Rationale	7
5	IMPLICATIONS FOR POLICY-MAKERS, PROGRAMME MANAGERS AND HEALTH-CARE PROVIDERS	8
	5.1 A woman's risk of HIV should not restrict her contraceptive choice	8
	5.2 Efforts to expand access to contraceptive options must continue	8
	5.3 A renewed emphasis on HIV and STI prevention services is urgently needed	9

CONTENTS (continued)

6	KNOWLEDGE GAPS AND AREAS FOR RESEARCH	9
	6.1 Contraceptive methods and HIV acquisition	9
	6.2 HIV prevention	9
	6.3 Community involvement	10
	6.4 Increased funding for high-quality, policy-relevant research	10
7	DISSEMINATION OF THIS GUIDANCE STATEMENT	10
	REFERENCES	11
	ANNEX 1. GUIDELINE DEVELOPMENT GROUP AND EVIDENCE SECRETARIAT	13
	ANNEX 2. DECLARATIONS OF CONFLICTS OF INTEREST	15
	ANNEX 3. GRADE EVIDENCE PROFILES	17
	ANNEX 4. EVIDENCE-TO-DECISION TABLE FOR HORMONAL CONTRACEPTIVE METHODS AND INTRAUTERINE DEVICES (IUDS)	21
	ANNEX 5: SYSTEMATIC REVIEWS	23

ACKNOWLEDGEMENTS

The World Health Organization (WHO) would like to thank the members of the Guideline Development Group and the Evidence Secretariat (Annex 1) for their contributions throughout the development of these important recommendations for women at high risk of HIV. WHO is very grateful for the suggestions provided by colleagues who peer reviewed the draft statement as members of the External Review Group.

The development of this technical statement was financially supported by the Bill & Melinda Gates Foundation, the Netherlands Ministry of Foreign Affairs, the United States Agency for International Development, and the United States National Institutes of Health.

ABBREVIATIONS

CIC	combined injectable contraceptive	HR	hazard ratio
COC	combined oral contraceptive	IRR	incidence rate ratio
CRE	WHO Office of Compliance, Risk Management and Ethics	IUD	intrauterine device
Cu-IUD	copper-bearing intrauterine device	LNG	levonorgestrel
DMPA	depot medroxyprogesterone acetate	LNG-IUD	levonorgestrel-releasing intrauterine device
DMPA-IM	intramuscular depot medroxyprogesterone acetate	MEC	<i>Medical eligibility criteria for contraceptive use</i>
DMPA-SC	subcutaneous depot medroxyprogesterone acetate	NET-EN	norethisterone enanthate
ECHO	Evidence for Contraceptive Options and HIV Outcomes (Study)	OTC	over the counter
ETG	etonogestrel	POP	progestogen-only pill
FDA	United States Food and Drug Administration	PrEP	pre-exposure prophylaxis (for HIV)
GDG	Guideline Development Group	RCT	randomized clinical trial
GRADE	Grading of Recommendations Assessment, Development and Evaluation	STI	sexually transmitted infection
		WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25083

